$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
[News Flash] Lumakras, the first KRAS-targeting drug for lung cancer, is approved by the FDA for marketing
2025-10-19 11:44:20
Check Details
How much does a box of Lumakras cost in 2021? Where can I buy imported Lumakras cheaper?
2025-10-19 11:44:20
Check Details
How long does it take for resistance to icotinib to develop? What are the symptoms of icotinib resistance?
2025-10-19 11:44:20
Check Details
How much does a box of the new lung cancer drug Icotinib cost? Can the targeted drug icotinib be purchased in domestic pharmacies?
2025-10-19 11:44:20
Check Details
Nivolumab/ipilimumab combination chemotherapy can treat advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
CLN-081 shows anti-tumor activity in first-in-human trial for treatment of mutation-positive non-small cell lung cancer_Canghule
2025-10-19 11:44:20
Check Details
Rybrevant, the first targeted therapy for refractory lung cancer, is here
2025-10-19 11:44:20
Check Details
Rybrevant, a new drug for non-small cell lung cancer, was approved for marketing, and when Rybrevant will be launched
2025-10-19 11:44:20
Check Details
Has the imported drug topotecan been approved for marketing in the country? Where can I buy topotecan?
2025-10-19 11:44:20
Check Details
[Drug Analysis] What is the difference between topotecan and irinotecan?
2025-10-19 11:44:20
Check Details
What cancer does the new anti-tumor drug topotecan treat? Is topotecan useful in small cell lung cancer?
2025-10-19 11:44:20
Check Details
How to buy topotecan? Is topotecan included in medical insurance?
2025-10-19 11:44:20
Check Details
1
2
...
3939
3940
3941
3942
3943
3944
3945
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide